PATH vs VYNE · P/E 19, rev $1.61B vs rev $501.0K
Uipath Inc (PATH) versus Vyne Therapeutics Inc (VYNE) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Vyne Therapeutics Inc (VYNE) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported VYNE revenue for 2024-12-31 was $501.0K. Net income was -$39.8M. Revenue was up 18.2% from 2023-12-31 to 2024-12-31. VYNE currently screens at market cap $21.1M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. VYNE currently screens at market cap $21.1M.
Not investment advice. Open the PATH and VYNE stock pages for the full models.
Not investment advice.